Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer acquires Canadian Trillium for US$2.3 Billion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 26, 2021 1:00pm

184 Views

Post# 33770032

RE:RE:RE:RE:RE:RE:Pfizer acquires Canadian Trillium for US$2.3 Billion

Jefferies analysts see the current drawdown in biotech stocks , with the XBI is down 25% from a peak in February, as setting the stage for some serious M&A, exemplified by Pfizer's acquisition of the pre-clinical / early stage immuno-oncology company Trillium Therapeutics this week.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market